An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
![Photograph of Jennifer Diamond](https://som.ucdenver.edu/FIMS/Content/faculty/11955/CU-Doctors-11955.jpg)
Jennifer Diamond
Study ID
Protocol Number: 21-4586
More information available at ClinicalTrials.gov: NCT05070247
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers